schliessen

Filtern

 

Bibliotheken

Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts

The authors compared the therapeutic effects of doxorubicin in two formulations: free in saline suspension and encapsulated in sterically stabilized liposomes composed of hydrogenated soy phosphatidylcholine/2cholesterol/polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine (Doxil, Liposome Techn... Full description

Journal Title: Cancer 01 March 1994, Vol.73(5), pp.1478-1484
Main Author: Vaage, Jan
Other Authors: Barberá‐Guillem, Emilio , Abra, Robert , Huang, Anthony , Working, Peter
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X ; E-ISSN: 1097-0142 ; DOI: 10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wjAID-CNCR2820730526>3.0.CO;2-1
title: Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
format: Article
creator:
  • Vaage, Jan
  • Barberá‐Guillem, Emilio
  • Abra, Robert
  • Huang, Anthony
  • Working, Peter
subjects:
  • Liposomes
  • Doxorubicin
  • Therapy
  • Prostate Carcinoma
ispartof: Cancer, 01 March 1994, Vol.73(5), pp.1478-1484
description: The authors compared the therapeutic effects of doxorubicin in two formulations: free in saline suspension and encapsulated in sterically stabilized liposomes composed of hydrogenated soy phosphatidylcholine/2cholesterol/polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine (Doxil, Liposome Technology, Inc., Menlo Park, CA). Laser scan microscope and microfluoro‐meter studies showed that the liposome‐encapsulated drug entered the liver, the kidneys, and the tumor in greater quantity and remained in the liver and in the tumor longer than the free drug. The liposome formulation produced a 25‐fold increase in doxorubicin at the disease site. Doxil was significantly more effective than the free drug in inhibiting growth and in effecting cures and had only minor and temporary systemic toxic effects. The current study demonstrated the therapeutic efficacy of doxorubicin, encapsulated in sterically stabilized liposomes, against prostate carcinoma. Decreased systemic elimination, increased penetration into the tumor, and long liposome presence with slow drug release into the tumor probably accounted for the enhanced therapeutic effect of doxorubicin in sterically stabilized liposomes. 1994; 73:1478–84. The drug formulations were injected intravenously to treat human prostate carcinoma PC‐3, implanted subcutaneously into nude Swiss mice. Confocal laser scan microscopy and microfluorometry were used to determine tissue distribution and to quantitate drug uptake.
language: eng
source:
identifier: ISSN: 0008-543X ; E-ISSN: 1097-0142 ; DOI: 10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1
fulltext: fulltext
issn:
  • 0008-543X
  • 0008543X
  • 1097-0142
  • 10970142
url: Link


@attributes
ID429755783
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidAID-CNCR2820730526>3.0.CO;2-1
sourceidwj
recordidTN_wjAID-CNCR2820730526>3.0.CO;2-1
sourcesystemOther
pqid76357101
galeid14956772
display
typearticle
titleTissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
creatorVaage, Jan ; Barberá‐Guillem, Emilio ; Abra, Robert ; Huang, Anthony ; Working, Peter
ispartofCancer, 01 March 1994, Vol.73(5), pp.1478-1484
identifier
subjectLiposomes ; Doxorubicin ; Therapy ; Prostate Carcinoma
descriptionThe authors compared the therapeutic effects of doxorubicin in two formulations: free in saline suspension and encapsulated in sterically stabilized liposomes composed of hydrogenated soy phosphatidylcholine/2cholesterol/polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine (Doxil, Liposome Technology, Inc., Menlo Park, CA). Laser scan microscope and microfluoro‐meter studies showed that the liposome‐encapsulated drug entered the liver, the kidneys, and the tumor in greater quantity and remained in the liver and in the tumor longer than the free drug. The liposome formulation produced a 25‐fold increase in doxorubicin at the disease site. Doxil was significantly more effective than the free drug in inhibiting growth and in effecting cures and had only minor and temporary systemic toxic effects. The current study demonstrated the therapeutic efficacy of doxorubicin, encapsulated in sterically stabilized liposomes, against prostate carcinoma. Decreased systemic elimination, increased penetration into the tumor, and long liposome presence with slow drug release into the tumor probably accounted for the enhanced therapeutic effect of doxorubicin in sterically stabilized liposomes. 1994; 73:1478–84. The drug formulations were injected intravenously to treat human prostate carcinoma PC‐3, implanted subcutaneously into nude Swiss mice. Confocal laser scan microscopy and microfluorometry were used to determine tissue distribution and to quantitate drug uptake.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Vaage, Jan
1Barberá‐Guillem, Emilio
2Abra, Robert
3Huang, Anthony
4Working, Peter
titleTissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
descriptionThe authors compared the therapeutic effects of doxorubicin in two formulations: free in saline suspension and encapsulated in sterically stabilized liposomes composed of hydrogenated soy phosphatidylcholine/2cholesterol/polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine (Doxil, Liposome Technology, Inc., Menlo Park, CA). Laser scan microscope and microfluoro‐meter studies showed that the liposome‐encapsulated drug entered the liver, the kidneys, and the tumor in greater quantity and remained in the liver and in the tumor longer than the free drug. The liposome formulation produced a 25‐fold increase in doxorubicin at the disease site. Doxil was significantly more effective than the free drug in inhibiting growth and in effecting cures and had only minor and temporary systemic toxic effects. The current study demonstrated the therapeutic efficacy of doxorubicin, encapsulated in sterically stabilized liposomes, against prostate carcinoma. Decreased systemic elimination, increased penetration into the tumor, and long liposome presence with slow drug release into the tumor probably accounted for the enhanced therapeutic effect of doxorubicin in sterically stabilized liposomes. 1994; 73:1478–84. The drug formulations were injected intravenously to treat human prostate carcinoma PC‐3, implanted subcutaneously into nude Swiss mice. Confocal laser scan microscopy and microfluorometry were used to determine tissue distribution and to quantitate drug uptake.
subject
0Liposomes
1Doxorubicin
2Therapy
3Prostate Carcinoma
general
0English
1Wiley Subscription Services, Inc., A Wiley Company
210.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1
3Wiley Online Library
sourceidwj
recordidwjAID-CNCR2820730526>3.0.CO;2-1
issn
00008-543X
10008543X
21097-0142
310970142
rsrctypearticle
creationdate1994
addtitleCancer
searchscope
0wj
1wiley
scope
0wj
1wiley
lsr30VSR-Enriched:[pages, galeid, pqid]
sort
titleTissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
authorVaage, Jan ; Barberá‐Guillem, Emilio ; Abra, Robert ; Huang, Anthony ; Working, Peter
creationdate19940301
facets
frbrgroupid7141370279355949683
frbrtype5
languageeng
creationdate1994
topic
0Liposomes
1Doxorubicin
2Therapy
3Prostate Carcinoma
collectionWiley Online Library
prefilterarticles
rsrctypearticles
creatorcontrib
0Vaage, Jan
1Barberá‐Guillem, Emilio
2Abra, Robert
3Huang, Anthony
4Working, Peter
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Vaage
1Barberá‐Guillem
2Abra
3Huang
4Working
aufirst
0Jan
1Emilio
2Robert
3Anthony
4Peter
au
0Vaage, Jan
1Barberá‐Guillem, Emilio
2Abra, Robert
3Huang, Anthony
4Working, Peter
atitleTissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
jtitleCancer
risdate19940301
volume73
issue5
spage1478
epage1484
issn0008-543X
eissn1097-0142
genrearticle
ristypeJOUR
abstractThe authors compared the therapeutic effects of doxorubicin in two formulations: free in saline suspension and encapsulated in sterically stabilized liposomes composed of hydrogenated soy phosphatidylcholine/2cholesterol/polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine (Doxil, Liposome Technology, Inc., Menlo Park, CA). Laser scan microscope and microfluoro‐meter studies showed that the liposome‐encapsulated drug entered the liver, the kidneys, and the tumor in greater quantity and remained in the liver and in the tumor longer than the free drug. The liposome formulation produced a 25‐fold increase in doxorubicin at the disease site. Doxil was significantly more effective than the free drug in inhibiting growth and in effecting cures and had only minor and temporary systemic toxic effects. The current study demonstrated the therapeutic efficacy of doxorubicin, encapsulated in sterically stabilized liposomes, against prostate carcinoma. Decreased systemic elimination, increased penetration into the tumor, and long liposome presence with slow drug release into the tumor probably accounted for the enhanced therapeutic effect of doxorubicin in sterically stabilized liposomes. 1994; 73:1478–84. The drug formulations were injected intravenously to treat human prostate carcinoma PC‐3, implanted subcutaneously into nude Swiss mice. Confocal laser scan microscopy and microfluorometry were used to determine tissue distribution and to quantitate drug uptake.
copNew York
pubWiley Subscription Services, Inc., A Wiley Company
doi10.1002/1097-0142(19940301)73:5<1478::AID-CNCR2820730526>3.0.CO;2-1
pages1478-14784
date1994-03-01